Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation

Head and Neck

Volumn 33, Issue 6, 2011, Pages 808-816

  Rueda, Antonio ^a   Cazorla, Oscar ^b   Pérez, Lidia ^c   Úlvarez, Martina ^c   Redondo, Maximino ^a   Gallego, Elena ^c   Sáez, Maribel ^c   Medina, José Antonio ^c   Solano, José ^c   Matilla, Alfredo ^c  

^a HOSPITAL COSTA DEL SOL   (Spain)

^b Hospital General   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

angiogenesis; chemotherapy; larynx; VEGF; VEGFR 2

Indexed keywords

CISPLATIN; FLUOROURACIL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CONTINUOUS INFUSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNGECTOMY; LARYNX CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGAN PRESERVATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79953713497     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21551     Document Type: Article

References (29)

1. [No authors listed] Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-1690.
2. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098. (Pubitemid 37464533)
3. American Society of Clinical Oncology, Pfister DG, Laurie SA, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006; 24: 3693-3704. (Pubitemid 46630546)
4. Seiwert TY, Cohen EE,. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008; 35: 274-285. (Pubitemid 351787696)
5. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E,. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 1997; 33: 369-374. (Pubitemid 28129241)
6. Denhart BC, Guidi AJ, Tognazzi K, Dvorak HF, Brown LF,. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 1997; 77: 659-664. (Pubitemid 28018787)
7. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z,. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22. (Pubitemid 29038270)
8. Ferrara N, Gerber HP, LeCouter J,. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676. (Pubitemid 36749215)
9. Neuchrist C, Erovic BM, Handisurya A, et al. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 2001; 111: 1834-1841. (Pubitemid 32946463)
10. Tong M, Lloyd B, Pei P, Mallery SR,. Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF. J Cell Biochem 2008; 105: 1202-1210.
11. Kyzas PA, Cunha IW, Ioannidis JP,. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005; 11: 1434-1440. (Pubitemid 40315223)
12. Parikh RR, Yang Q, Haffty BG,. Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer 2007; 109: 566-573. (Pubitemid 46190965)
13. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ,. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 2005; 18: 485-494. (Pubitemid 40478111)
14. Marioni G, Giacomelli L, D'Alessandro E, et al. Laryngeal carcinoma recurrence rate and disease-free interval are related to CD105 expression but not to vascular endothelial growth factor 2 (Flk-1/Kdr) expression. Anticancer Res 2008; 28: 551-557. (Pubitemid 351362869)
15. Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008; 26: 1732-1741.
16. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-257.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A,. Reporting results of cancer treatment. Cancer 1981; 47: 207-214. (Pubitemid 11167383)
18. Spaulding MB, Fischer SG, Wolf GT,. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol 1994; 12: 1592-1599. (Pubitemid 24244994)
19. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098. (Pubitemid 37464533)
20. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704. (Pubitemid 350005151)
21. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715. (Pubitemid 350005152)
22. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101: 498-506.
23. American Society of Clinical Oncology, Pfister DG, Laurie SA, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006; 24: 3693-3704. (Pubitemid 46630546)
24. Forastiere AA, Trotti AM,. Searching for less toxic larynx preservation: a need for common definitions and metrics. J Natl Cancer Inst 2009; 101: 129-131.
25. Lorch JH, Posner MR, Wirth LJ, Haddad RI,. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am 2008; 22: 1155-1163.
26. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006; 24: 593-598. (Pubitemid 46630421)
27. Worden FP, Moyer J, Lee JS, et al. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope 2009; 119: 1510-1517.
28. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008; 26: 3138-3146.
29. Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008; 26: 1732-1741.